Akebia Therapeutics, Inc. - Common Stock (AKBA)
2.0400
-0.8000 (-28.17%)
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease
The company is primarily engaged in addressing unmet medical needs in anemia caused by chronic kidney disease, aiming to enhance patient outcomes through its proprietary treatments and drug candidates. Akebia's research and development efforts are centered around creating therapies that improve the management of renal diseases by promoting better health and quality of life for patients suffering from kidney-related conditions.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · March 20, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 20, 2025
Via Benzinga · March 20, 2025
Via Benzinga · March 20, 2025
Via Benzinga · March 20, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · March 19, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 18, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · March 14, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · March 14, 2025
Via Benzinga · March 14, 2025

AKBA stock results show that Akebia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

Via Benzinga · April 10, 2024

Via Benzinga · March 28, 2024

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.
Via Benzinga · March 28, 2024

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.
Via Benzinga · March 28, 2024

Via Benzinga · March 28, 2024

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.
Via Benzinga · March 27, 2024